Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholangiopancreatography pancreatitis

被引:17
|
作者
Park, Chan Hyuk [1 ]
Park, Se Woo [2 ]
Yang, Min Jae [3 ]
Moon, Sung Hoon [4 ]
Park, Da Hae [2 ]
机构
[1] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri, South Korea
[2] Hallym Univ, Dongtan Sacred Heart Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea
[3] Ajou Univ, Dept Gastroenterol, Sch Med, Suwon, South Korea
[4] Hallym Univ, Coll Med, Div Gastroenterol, Dept Internal Med,Sacred Heart Hosp, Anyang, South Korea
关键词
Endoscopic retrograde cholangiopancreatography; Pancreatitis; Risk; Prediction; Score; DOUBLE-GUIDEWIRE TECHNIQUE; ERCP PANCREATITIS; CANNULATION; COMPLICATIONS; PREVENTION; EFFICACY;
D O I
10.1007/s00464-021-08491-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common serious adverse event. Given recent endoscopic advances, we aimed to develop and validate a risk prediction model for PEP using the latest clinical database. Methods We analyzed the data of patients with naive papilla who underwent endoscopic retrograde cholangiopancreatography (ERCP). Pre-ERCP and post-ERCP risk prediction models for PEP were developed using logistic regression analysis. Patients were classified into low- (0 points), intermediate- (1-2 points), and high-risk (>= 3 points) groups according to point scores. Results We included 760 and 735 patients in the derivation and validation cohorts, respectively. The incidence of PEP was 5.5% in the derivation cohort and 3.9% in the validation cohort. Age <= 65 (1 point), female sex (1 point), acute pancreatitis history (2 points), malignant biliary obstruction (2 points [pre-ERCP model] or 1 point [post-ERCP model]), and pancreatic sphincterotomy (2 points, post-ERCP model only) were independent risk factors. In the validation cohort, the high-risk group (>= 3 points) had a significantly higher risk of PEP compared to the low- or intermediate-risk groups under the post-ERCP risk prediction model (low: 2.0%; intermediate: 3.4%; high: 18.4%), while there was no significant between-group difference under the pre-ERCP risk prediction model (low: 2.2%; intermediate: 3.8%; high: 6.9%). Conclusions We developed and validated pre-ERCP and post-ERCP risk prediction models. In the latter, the high-risk group had a higher risk of PEP development than the low- or intermediate-risk groups. Our study findings will help clinicians stratify patient risk for the development of PEP.
引用
收藏
页码:2052 / 2061
页数:10
相关论文
共 50 条
  • [31] Development and validation of a practical clinical risk prediction model for post-endoscopic retrograde cholangiopancreatography pancreatitis
    Meng, Zhao Wu
    Ruan, Yibing
    Fisher, Stacey
    Bishay, Kirles
    Chau, Millie
    Howarth, Megan
    Cartwright, Shane
    Chen, Yen-, I
    Dixon, Elijah
    Heitman, Steven J.
    Brenner, Darren R.
    Forbes, Nauzer
    DEN OPEN, 2024, 4 (01):
  • [32] Development and external validation of a nomogram for prediction of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Fukuda, Rintaro
    Hakuta, Ryunosuke
    Nakai, Yousuke
    Hamada, Tsuyoshi
    Takaoka, Shinya
    Tokito, Yurie
    Suzuki, Yukari
    Oyama, Hiroki
    Kanai, Sachiko
    Noguchi, Kensaku
    Suzuki, Tatsunori
    Ishigaki, Kazunaga
    Saito, Kei
    Saito, Tomotaka
    Takahara, Naminatsu
    Mizuno, Suguru
    Ito, Yukiko
    Kogure, Hirofumi
    Fujishiro, Mitsuhiro
    PANCREATOLOGY, 2023, 23 (07) : 789 - 796
  • [33] Is post-endoscopic retrograde cholangiopancreatography pancreatitis the same as acute clinical pancreatitis?
    Tetsuya Mine
    Journal of Gastroenterology, 2007, 42 : 265 - 266
  • [34] Post-endoscopic retrograde cholangiopancreatography pancreatitis: Risk stratification and appropriate patient selection
    Moran, Robert A.
    Akshintala, Venkata S.
    Singh, Vikesh K.
    TECHNIQUES IN GASTROINTESTINAL ENDOSCOPY, 2014, 16 (04) : 156 - 161
  • [35] Does Intravenous Toradol Lower the Risk for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis?
    Al-Hamid, Hussein
    Manatsathit, Wuttiporn
    Chausse, Steve
    Ballout, Hussein
    Barawi, Mohammed
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S576 - S576
  • [36] Is post-endoscopic retrograde cholangiopancreatography pancreatitis the same as acute clinical pancreatitis?
    Mine, Tetsuya
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (03) : 265 - 266
  • [37] Does Intravenous Toradol Lower the Risk for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis?
    Al-Hamid, Hussein
    Leelasinjaroen, Pornchai
    Manatsathit, Wuttiporn
    Barawi, Mohammed
    GASTROINTESTINAL ENDOSCOPY, 2016, 83 (05) : AB254 - AB254
  • [38] Increased fat in pancreas not associated with risk of pancreatitis post-endoscopic retrograde cholangiopancreatography
    Pokhrel, Bhupesh
    Choi, Eun Kwang
    Khalid, Omer
    Sandrasegaran, Kumar
    Fogel, Evan L.
    McHenry, Lee
    Sherman, Stuart
    Watkins, James
    Cote, Gregory A.
    Pitt, Henry A.
    Zyromski, Nicholas J.
    Juliar, Beth
    Lehman, Glen A.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 199 - 204
  • [39] No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Hirotoshi Ishiwatari
    Takahiro Urata
    Ichiro Yasuda
    Shimpei Matsusaki
    Hiroyuki Hisai
    Hiroshi Kawakami
    Michihiro Ono
    Takuji Iwashita
    Shinpei Doi
    Kazumichi Kawakubo
    Tsuyoshi Hayashi
    Tomoko Sonoda
    Naoya Sakamoto
    Junji Kato
    Digestive Diseases and Sciences, 2016, 61 : 3292 - 3301
  • [40] Pancreatic Stents for prevention of post-endoscopic retrograde Cholangiopancreatography pancreatitis
    Freeman, Martin L.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (11) : 1354 - 1365